|
Market Closed -
Sao Paulo
21:09:00 18/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 75.00 BRL | -7.06% |
|
+8.38% | +13.71% |
| 09-16 | Sling Therapeutics raises $123 million to advance thyroid eye disease drug | RE |
| 09-15 | Amgen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 126,718 | 140,139 | 154,142 | 140,103 | 176,250 | 208,495 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 18.29% | - | - |
| Enterprise Value (EV) 1 | 151,990 | 169,779 | 207,811 | 188,229 | 221,725 | 249,980 | 244,311 | 239,308 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 12.74% | -2.27% | -2.05% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 24.4x | 21.9x | 21.1x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 18.4x | 15x | 12.1x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.2x | 1.9x | 5.74x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 5.35x | 5.18x | 5.02x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 6.42x | 6.07x | 5.76x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 11.4x | 11x | 10.7x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 14.7x | 13.8x | 13x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 22.5x | 16.6x | 15.6x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 4.45% | 6.03% | 6.43% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.62% | 2.76% | 2.88% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.79 | 17.65 | 18.3 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 63.9% | 60.4% | 60.8% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,938 | 40,233 | 41,542 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,864 | 22,213 | 22,322 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,964 | 17,664 | 18,357 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,678 | 9,342 | 9,972 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,485 | 35,817 | 30,814 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 385.65 | 385.65 | 385.65 |
| Nbr of stocks (in thousands) | 563,266 | 533,579 | 535,178 | 537,533 | 538,481 | 540,632 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 16.45x | 6.48x | 15.87x | 2.44% | 400.19B | |
| Weighted average by Cap. | 23.68x | 7.73x | 17.83x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
